Literature DB >> 9247415

Augmentation of clozapine therapy with ondansetron.

J K Briskin, J L Curtis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247415     DOI: 10.1176/ajp.154.8.1171a

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  5 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

2.  Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.

Authors:  A P Rajkumar; B Poonkuzhali; A Kuruvilla; A Srivastava; M Jacob; K S Jacob
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

Review 3.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.

Authors:  Maryam Noroozian; Sina Ghasemi; Seyed-Mohammad-Reza Hosseini; Amirhossein Modabbernia; Mohammad-Reza Khodaie-Ardakani; Omid Mirshafiee; Mehdi Farokhnia; Masih Tajdini; Farzin Rezaei; Bahman Salehi; Mandana Ashrafi; Habibeh Yekehtaz; Mina Tabrizi; Shahin Akhondzadeh
Journal:  Psychopharmacology (Berl)       Date:  2013-03-21       Impact factor: 4.530

5.  Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial.

Authors:  Roya Samadi; Susan Soluti; Reza Daneshmand; Shervin Assari; Ali Akhoundpour Manteghi
Journal:  Iran J Med Sci       Date:  2017-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.